![]() |
市場調査レポート
商品コード
1654669
不活化ワクチンの世界市場:2025年~2033年Global Inactivated Vaccines Market - 2025-2033 |
||||||
カスタマイズ可能
適宜更新あり
|
不活化ワクチンの世界市場:2025年~2033年 |
出版日: 2025年02月13日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 即日から翌営業日
|
世界の不活化ワクチン市場は、2024年に226億米ドルに達し、2033年までには342億6,000万米ドルに達すると予測され、予測期間中の2024年から2032年のCAGRは4.8%で成長する見込みです。
ワクチンは、様々な種類の感染症に対する免疫力を人々に提供する生物学的製品です。ワクチンは、弱毒化、不活化、または病原体の残骸から構成され、投与されると身体の免疫システムを誘発し、抗体の産生を助けます。不活化ワクチンは、死滅した病原体からなるもので、免疫力が長続きしません。不活化ワクチンでは、必要な免疫レベルを得るために、繰り返し投与(ブースター投与)する必要があります。
不活化ワクチンで最もよく治療される病原体感染症は、ポリオ、狂犬病、ジフテリア、破傷風、百日咳、季節性インフルエンザ、A型肝炎、日本脳炎などです。
促進要因と抑制要因
世界の予防接種プログラムの増加
ワクチンは予防ヘルスケアにおいて極めて重要であり、感染症による世界の負担を回避します。ワクチン接種は、ポリオ、ジフテリア、破傷風、百日咳などの致死的感染症から新生児を予防するために、世界中で日常的に行われているヘルスケアです。世界保健機関(WHO)や国連児童基金(ユニセフ)などの世界の保健機関は、これらの感染症の撲滅を目指したワクチン接種プログラムに積極的に取り組んでいます。これらのプログラムは、不活化ワクチンへのアクセスを改善し、市場成長を後押しする不活化ワクチンへの高い需要を生み出すと予測されています。
例えば、世界保健機関は最近、野生ポリオウイルス1型(WPV1)を2027年末までに根絶し、循環型2型変種ポリオウイルス(cVDPV2/ワクチン由来ポリオウイルス)を2029年末までに根絶するため、ポリオ根絶戦略2022-2026を2029年末まで延長しました。このプログラムは世界各国政府から支持され、プログラム延長のために約24億米ドルの資金が提供されました。このプログラム延長の主な成果は、ワクチン接種率の向上であり、メーカーにとっては販売額と販売量の改善につながり、市場成長の原動力にもなっています。
サプライチェーンの不一致は市場成長を抑制する可能性があります。
サプライチェーンの不一致は、ワクチン接種率を低下させ、世界の予防接種プログラムに影響を与え、市場全体を混乱させることにより、不活化ワクチン市場に多大な影響を与える可能性があります。このようなサプライチェーンの不一致は、世界の需要を上回る限定的な生産、限られた製造業者、突発的なアウトブレイクなどによって引き起こされます。例えば、2024年には世界保健機関(WHO)によってコレラの大流行が報告され、26カ国から30万7,433人の患者と2,326人の死者が出ました。不活化コレラワクチンであるデュコラルの需要が高まっており、このワクチン不足は英国を含む様々な国で報告されました。このようにワクチンの供給が限られていることは、より大きな需要を生かす機会を妨げることになりかねません。
The global inactivated vaccines market reached US$ 22.60 billion in 2024 and is expected to reach US$ 34.26 billion by 2033, growing at a CAGR of 4.8% during the forecast period 2024-2032.
Vaccines are biological products that provide immunity to people against various types of infections. Vaccines consist of live-attenuated, inactivated, or remnants of pathogens, which trigger the body's immune system when administered, and aid in the production of antibodies. Inactivated vaccines are those which consist of killed pathogens, and do not provide immunity that lasts long. With inactivated vaccines, repeated doses (booster doses) are necessary to attain the required level of immunity.
The most commonly treated pathogenic infections with inactivated vaccines are polio, rabies, diphtheria, tetanus, pertussis, seasonal influenza, hepatitis A, Japanese encephalitis, etc.
Market Dynamics: Drivers & Restraints
The rising immunization programs across the globe
Vaccines are crucial in preventive healthcare, avoiding the global burden of infectious diseases. Vaccination is a routine healthcare practice worldwide to immunize newborns against deadly infections such as polio, diphtheria, tetanus, and pertussis. Global health organizations such as the World Health Organization (WHO), the United Nations Children's Fund (UNICEF), and others are actively involved in vaccination programs aiming to eradicate these infections. These programs are anticipated to improve access to inactivated vaccines and create a higher demand for them propelling their market growth.
For instance, global health organizations have recently extended the Polio Eradication Strategy 2022-2026 to the end of 2029 to eradicate wild poliovirus type 1 (WPV1) by the end of 2027 and eliminate circulating type 2 variant poliovirus (cVDPV2/ vaccine-derived poliovirus) by the end of 2029. This program was supported by governments across the world and has provided a fund of nearly US$ 2.4 billion for the extended program. The major outcome of this program extension is an improved vaccination rate benefiting the manufacturers to improve their sales value and volume, also driving market growth.
Supply chain discrepancies may restrain the market growth.
Supply chain discrepancies can tremendously impact the market of inactivated vaccines, by reducing vaccine coverage, impacting the global immunization programs, and deflecting the overall market. These supply chain discrepancies are caused by limited production outpaced by global demand, limited manufacturers, sudden outbreaks, etc. For instance, in 2024, a cholera outbreak was reported by the World Health Organization, with 307,433 cases and 2,326 deaths from 26 countries. There is a higher demand for Dukoral, an inactivated cholera vaccine, and this vaccine shortage was reported in various countries including the United Kingdom. This limited supply of vaccines can hinder the opportunity to capitalize on the larger demand.
The global inactivated vaccines market is segmented based on pathogen, vaccine type, and region.
Influenza vaccine in the vaccine type segment is dominating the market.
Influenza vaccines also known as flu shots are the ones that protect the recipient against influenza viruses which cause respiratory illnesses. Vaccination is currently the best preventive measure to fight influenza viruses. As per the World Health Organization (WHO), between 3 to 5 million severe influenza cases are reported each year, and 290k to 650k respiratory deaths. The WHO also states that the influenza virus is constantly evolving which requires frequent reformulation of influenza vaccines, and annual immunization. The inactivated influenza vaccines are the most widely used and are categorized as trivalent (3 strains; TIV) and quadrivalent (4 strains; QIV). These vaccines possess excellent safety profiles with minimal side effects and can be prescribed to anyone above 6 months of age, including special populations such as pregnant women.
The market for influenza vaccines is high among all the inactivated vaccines, majorly due to their higher demand during flu season each year, and frequency of administration. The Global Vaccine Report by the WHO states that Influenza vaccines are the ones with high sales value and volume as they are sold in high-income countries where the disease burden is also high.
North America dominated the inactivated vaccines market.
North America region is well known for its advanced healthcare system, public health policies, and immunization programs. The U.S., which is the global leader in the healthcare industry, houses vaccine manufacturers who sell advanced vaccines, meeting the demands of the country. As the U.S. is a high-income country there is a clear disparity in the prices they pay as compared to other nations of the world. Manufacturers tend to generate most of their revenue from the region due to higher vaccine costs, which is a major contributor to the region's dominance.
For instance, influenza vaccine is the dominating one in the inactivated vaccines market. Sanofi is a global leader in the manufacturing and supply of inactivated influenza vaccines. In 2023, the company reported a sale of 2,699 Euro million (2,886 USD million) for influenza vaccines of which ~52% of the sales are from the U.S. market.
The burden of infectious diseases is also high in the region, creating a higher demand for inactivated vaccines. For instance, as per the Centers for Disease Control and Prevention (CDC), in the U.S. nearly 40 million respiratory illnesses, 470k hospitalizations, and 28k deaths resulted from influenza infections in 2023-2024.
All these factors reflect why the North America region, especially the U.S. dominates the global inactivated vaccines market.
The major global players in the inactivated vaccines market are Serum Institute of India Pvt. Ltd., GSK plc., Sanofi., Biological E Limited., Bharat Biotech., Bio Farma, Merck & Co., Inc., Valneva SE., Pfizer Inc., and KM Biologics among others.
The global melanoma therapeutics market report would provide approximately 54 tables, 46 figures, and 195 pages.
Key Market Players
LIST NOT EXHAUSTIVE